ArticleMedical oncology (Northwood, London, England)2025
Combined Inhibition of telomerase and mitochondria synergistically promote apoptosis in AML cell lines.
Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the significant anti-proliferative effects of telomerase inhibition on acute myeloid leukemia (AML) cells, complementary therapies that promote apoptosis on AML cells have been suggested. This investigation assessed the impact of concurrently targeting telomerase with BIBR1532 and mitochondrial function with Tigecycline on inducing apoptosis in AML cell models. KG-1a and KG-1 AML cells were treated with IC50 concentrations of the telomerase inhibitor BIBR1532 and the mitochondrial inhibitor Tigecycline, both alone and in combination, for 48 h. Cell viability were assessed by MTT assay and Combination Index. Apoptosis was analyzed by Annexin V/7AAD staining using flow cytometry. Gene expression (Bax, Bad, Bcl-2, Bcl-xl, hTERT) was evaluated by quantitative real-time PCR (qRT-PCR), and Bax/Bcl-2 protein levels were measured by ELISA. Telomere length was determined by real-time PCR. Our result showed that, Co-inhibition of telomerase and mitochondria with IC50 values of BIBR1532 and Tigecycline for 48 h synergistically reduced the proliferation rate of AML (KG-1a and KG-1) cells. Besides, telomerase and mitochondria inhibition (TI/MI) synergistically augmented induction of apoptosis coupled with the up-regulation of Bax, Bad genes and down-regulation of Bcl-2, Bcl-xl and hTERT on AML cells. Also, TI/MI significantly changed Bax and Bcl-2 protein levels and reduced telomere length. In conclusion, the combined use of TI/MI induced anti-proliferative effects and induction of apoptosis by down-regulation of anti-apoptotic and up-regulation of pro-apoptotic genes and proteins levels and shortening of telomere length on AML cells.
Indexed as
Identifiers
41251865What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.